MetaCap

Oruka Therapeutics Inc. (ORKA)

NASDAQ: ORKAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

95.81-1.76 (-1.80%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ORKA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.12
Ex-dividend date
Aug 29, 2024
52-week range
25.23 – 115.52
Day range
93.30 – 97.24
Volume / Avg
1.98M / 965.27K
Beta
—

52-week range

$25.23$115.52

ORKA stock today

Oruka Therapeutics (ORKA) closed at $95.81 on Nov 20, down 1.80% (-$1.76), versus the S&P 500's 3.70% decline. Volume was 2.0x the average at 1.98M shares, a sign of unusually heavy trading. Shares are 17.1% below their 52-week high of $115.52, set on Aug 19, 2026 and 279.7% above the 52-week low of $25.23, in the middle of the past year's range.

ORKA is up 216.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 227.1%. Oruka Therapeutics has posted a net loss over the last twelve months (EPS of -$2.12), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Oruka Therapeutics

Company profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Dr. Lawrence Otto Klein Ph.D.
Headquarters
Menlo Park, CA
Employees
68

Financial highlights

Full financials

Oruka Therapeutics reported a net loss of $105.4 million, compared with a loss of $5.3 million a year earlier.

Oruka Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2023FY 2022FY 2021FY 2020
Revenue—$0$0$0$0
Growth—————
Net income$-105.43M$-5.34M$-9.93M$-19.32M$-9.74M
EPS (diluted)—$-0.37$-0.69$-1.39$-2.07

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$156.17+63.00%

  • Strong buy 2
  • Buy 11
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $117.00High $200.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.63 vs $-0.68
Surprise
+7.35%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$19.36
Ex-dividend date
Aug 29, 2024

ORKA news

All ORKA news

Oruka Therapeutics peers

Health Care sector
ORKA peer companies
CompanyPrice% ChgMarket capCompare
LNTHLantheus Holdings Inc.102.100.00%$6.68Bvs ORKA
NEOGNeogen Corporation10.55-2.77%$2.30Bvs ORKA
CLDXCelldex Therapeutics Inc.27.42-1.93%$2.15Bvs ORKA
NTLAIntellia Therapeutics Inc.10.00+5.04%$1.40Bvs ORKA
QUITAchieve Life Sciences Inc.5.56-5.28%$573.25Mvs ORKA
QDELQuidelOrtho Corporation8.32-6.73%$570.86Mvs ORKA
MYGNMyriad Genetics Inc.5.46-1.44%$523.74Mvs ORKA
TKNOAlpha Teknova Inc.7.63-2.30%$479.95Mvs ORKA

Indexes, lists and sector

Oruka Therapeutics stock FAQ

What is Oruka Therapeutics's stock price today?

ORKA last traded at $95.81 as of Nov 20, 4:00 PM EST, down 1.80% on the day. Prices are delayed at least 15 minutes.

Does Oruka Therapeutics pay a dividend?

Yes. Oruka Therapeutics pays $0.00 per share annually. The most recent dividend of $19.36 had an ex-dividend date of Aug 29, 2024.

Who is Oruka Therapeutics's CEO?

Dr. Lawrence Otto Klein Ph.D. is the chief executive officer of Oruka Therapeutics Inc., which has about 68 employees.

Has ORKA ever split its stock?

Yes. The most recent ORKA stock split was a 1-for-12 split on Sep 3, 2024, one of 6 splits on record.

What is the ORKA 52-week high?

The 52-week high for ORKA is $115.52 and the 52-week low is $25.23. The stock is currently 17.1% below its high.

Compare ORKA